Compare EVC & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVC | BCYC |
|---|---|---|
| Founded | 1996 | 2009 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 335.0M | 310.7M |
| IPO Year | 2000 | 2019 |
| Metric | EVC | BCYC |
|---|---|---|
| Price | $8.76 | $4.16 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $13.90 |
| AVG Volume (30 Days) | ★ 3.6M | 268.1K |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | ★ 5.35% | N/A |
| EPS Growth | ★ 47.59 | N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $536,034,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $69.77 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.95 | $4.20 |
| 52 Week High | $10.12 | $9.36 |
| Indicator | EVC | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 58.58 | 33.87 |
| Support Level | $2.70 | N/A |
| Resistance Level | $10.12 | $4.75 |
| Average True Range (ATR) | 0.73 | 0.18 |
| MACD | -0.19 | -0.03 |
| Stochastic Oscillator | 47.55 | 11.94 |
Entravision Communications Corp owns and operates Spanish language television and radio stations in the United States. The Company also owns and operates a smaller group of television stations that broadcast English language programming and has operations that provide programmatic advertising technology and services. The Company has organized its operations into two reportable segments. Its media segment includes its television, radio, and digital marketing operations. Its advertising and technology services segment provides programmatic advertising and technology services. The company generates the majority of its revenue from the advertising and technology services segment. Geographically, the company generates the majority of its revenue from the United States.
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.